BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35871672)

  • 21. Axillary Downstaging in Occult Primary Breast Cancer After Neoadjuvant Chemotherapy.
    Botty Van den Bruele A; Lavery J; Plitas G; Pilewskie ML
    Ann Surg Oncol; 2021 Feb; 28(2):968-974. PubMed ID: 32813202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical Management of the Axilla in Patients with Occult Breast Cancer (cT0 N+) After Neoadjuvant Chemotherapy.
    Cohen BL; Collier AL; Kelly KN; Goel N; Kesmodel SB; Yakoub D; Moller M; Avisar E; Franceschi D; Macedo FI
    Ann Surg Oncol; 2020 Jun; 27(6):1830-1841. PubMed ID: 31989360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Impact of Neoadjuvant Chemotherapy on Margin Re-excision in Breast-Conserving Surgery.
    Devane LA; Baban CK; O'Doherty A; Quinn C; McDermott EW; Prichard RS
    World J Surg; 2020 May; 44(5):1547-1551. PubMed ID: 32002582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgical Management of the Axilla in Invasive Lobular Carcinoma in the Z1071 Era: A Propensity-Score Matched Analysis of the National Cancer Database.
    Sinner HF; Naffouje S; Selfridge JM; Lee MC; Hoover SJ; Laronga C
    Curr Oncol; 2022 Oct; 29(11):8197-8206. PubMed ID: 36354707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery-A systematic review and meta-analysis.
    O'Connor DJ; Davey MG; Barkley LR; Kerin MJ
    Breast; 2022 Feb; 61():1-10. PubMed ID: 34864494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraoperative Touch Imprint Cytology in Targeted Axillary Dissection After Neoadjuvant Chemotherapy for Breast Cancer Patients with Initial Axillary Metastasis.
    Wu S; Wang Y; Zhang N; Li J; Xu X; Shen J; Liu G
    Ann Surg Oncol; 2018 Oct; 25(11):3150-3157. PubMed ID: 30083833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67.
    Boughey JC; Hoskin TL; Goetz MP
    Ann Surg Oncol; 2022 Sep; 29(9):5747-5756. PubMed ID: 35569077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of oncoplastic breast surgery in the management of breast cancer treated with primary chemotherapy.
    Mazouni C; Naveau A; Kane A; Dunant A; Garbay JR; Leymarie N; Sarfati B; Delaloge S; Rimareix F
    Breast; 2013 Dec; 22(6):1189-93. PubMed ID: 24054903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts.
    Weiss A; Martínez-Sáez O; Waks AG; Laws A; McGrath M; Tarantino P; Portnow L; Winer E; Rey M; Tapia M; Prat A; Partridge AH; Tolaney SM; Cejalvo JM; Mittendorf EA; King TA
    Cancer; 2023 Jun; 129(12):1836-1845. PubMed ID: 36951169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
    Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
    Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis.
    Wong SM; Weiss A; Mittendorf EA; King TA; Golshan M
    Ann Surg Oncol; 2019 Oct; 26(11):3517-3525. PubMed ID: 31342389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.
    Weiss A; Wong S; Golshan M; Freedman RA; Metzger O; Bellon J; Mittendorf EA; King TA
    Ann Surg Oncol; 2019 Dec; 26(13):4326-4336. PubMed ID: 31562601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemotherapy for stage II-III breast cancer: a single-center experience.
    Zaher HAE; Fathy H; Abozeid M; Faisal M
    World J Surg Oncol; 2023 Oct; 21(1):314. PubMed ID: 37805553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment.
    Chou HH; Chung WS; Ding RY; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Lo YF; Chen SC
    BMC Surg; 2021 Mar; 21(1):160. PubMed ID: 33757489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incorporating Lymphovenous Anastomosis in Clinically Node-Positive Women Receiving Neoadjuvant Chemotherapy: A Shared Decision-Making Model and Nuanced Approached to the Axilla.
    Lustig DB; Temple-Oberle C; Bouchard-Fortier A; Quan ML
    Curr Oncol; 2023 Apr; 30(4):4041-4051. PubMed ID: 37185419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
    Simons JM; Koppert LB; Luiten EJT; van der Pol CC; Samiei S; de Wilt JHW; Siesling S; Smidt ML
    Breast Cancer Res Treat; 2020 Apr; 180(3):725-733. PubMed ID: 32180074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surgical Axillary Staging Before Neoadjuvant Chemotherapy: Who Gets It and Why We Should Avoid It.
    Iles K; Strassle PD; Agala CB; Button J; Downs-Canner S
    Ann Surg Oncol; 2021 Oct; 28(10):5788-5797. PubMed ID: 34379251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit.
    Spronk PER; Volders JH; van den Tol P; Smorenburg CH; Vrancken Peeters MTFD
    Eur J Surg Oncol; 2019 Feb; 45(2):110-117. PubMed ID: 30348601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
    Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
    Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study.
    Puig CA; Hoskin TL; Day CN; Habermann EB; Boughey JC
    Ann Surg Oncol; 2017 May; 24(5):1242-1250. PubMed ID: 28000076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.